John Hunt

List of Publications by Year in Descending Order

66 papers	4,271 citations	33 h-index	65 g-index
70 ext. papers	4,530 ext. citations	5.4 avg, IF	4.23 L-index

#	Paper	IF	Citations
66	Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy. *ACS Medicinal Chemistry Letters*, **2021**, 12, 494-501	4.3	4
65	Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors. *ACS Medicinal Chemistry Letters*, **2021**, 12, 1143-1150	4.3	1
64	Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor. *Molecular Cancer Therapeutics*, **2021**, 20, 467-476	6.1	12
63	Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. *ACS Medicinal Chemistry Letters*, **2021**, 12, 288-294	4.3	7
62	Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor **2021**, 9,		12
61	Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance. *PLoS ONE*, **2019**, 14, e0212670	3.7	19
60	Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 732-736	2.9	13
59	Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 3249-3254	11.5	108
58	Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 582-585	2.9	20
57	Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors. *ACS Medicinal Chemistry Letters*, **2015**, 6, 523-7	4.3	61
56	BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 1905-9	2.9	8
55	Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport. *Experimental Cell Research*, **2015**, 338, 251-60	4.2	6
54	Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. *Cancer Immunology, Immunotherapy*, **2013**, 62, 1533-45	7.4	67
53	Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complex. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 4107-11	2.9	6
52	Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. *Clinical Cancer Research*, **2011**, 17, 4031-41	12.9	21
51	The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. *Molecular Cancer Therapeutics*, **2010**, 9, 369-78	6.1	63
50	Discovery of ixabepilone. *Molecular Cancer Therapeutics*, **2009**, 8, 275-81	6.1	84

49	Site-specific biotinylation. *International Journal of Peptide and Protein Research*, **2009**, 40, 567-574		4
48	Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxa (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. *Journal of Medicinal Chemistry*, **2009**, 52, 1251-4	8.3	252
47	Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. *Journal of Medicinal Chemistry*, **2008**, 51, 5330-41	8.3	110
46	Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropan a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). *Journal of Medicinal Chemistry*, **2008**, 51, 1976-80	8.3	110
45	Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1354-8	2.9	22
44	Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1945-51	2.9	53
43	Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amin (BMS-645737), an in vivo active potent VEGFR-2 inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2985-9	2.9	16
42	Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3224-9	2.9	58
41	Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. *Clinical Cancer Research*, **2006**, 12, 6186-93	12.9	71
40	Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. *Journal of Medicinal Chemistry*, **2006**, 49, 2143-6	8.3	119
39	Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. *Journal of Medicinal Chemistry*, **2006**, 49, 3766-9	8.3	39
38	Discovery of BMS-387032, a Potent Cyclin-Dependent Kinase Inhibitor in Clinical Development. *Enzyme Inhibitors Series*, **2006**, 251-264		
37	Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 3991-4008	8.3	59
36	Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 389-93	2.9	42
35	Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1895-9	2.9	20
34	New dual inhibitors of EGFR and HER2 protein tyrosine kinases. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 4774-9	2.9	39
33	Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1429-33	2.9	34
32	Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. *Cancer Research*, **2004**, 64, 3974-80	10.1	18

31	The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 6107-11	2.9	30
30	Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template. *Journal of Medicinal Chemistry*, **2004**, 47, 4054-9	8.3	86
29	Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. *Journal of Medicinal Chemistry*, **2004**, 47, 6658-61	8.3	1066
28	N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. *Journal of Medicinal Chemistry*, **2004**, 47, 1719-28	8.3	229
27	Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. *Journal of Medicinal Chemistry*, **2002**, 45, 3905-27	8.3	149
26	Farnesyltransferase Inhibitors: From Squalene Synthase Inhibitors to the Clinical Agent BMS-214662. *ACS Symposium Series*, **2001**, 199-213	0.4	
25	3-Imidazolylmethylaminophenylsulfonyltetrahydroquinolines, a novel series of farnesyltransferase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 273-5	2.9	27
24	Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. *Journal of Medicinal Chemistry*, **2000**, 43, 3587-95	8.3	123
23	Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. *Journal of Medicinal Chemistry*, **2000**, 43, 4126-34	8.3	95
22	Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase. *Journal of Medicinal Chemistry*, **1999**, 42, 5241-53	8.3	43
21	Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2∀amino-N- (3,4-dimethyl-5-isoxazolyl)-4∀(2-methylpropyl)[1, 1∀biphenyl]-2-sulfonamide (BMS-187308). *Journal of Medicinal Chemistry*, **1998**, 41, 5198-218	8.3	33
20	Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. *Journal of Medicinal Chemistry*, **1996**, 39, 353-8	8.3	88
19	Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. *Journal of Medicinal Chemistry*, **1996**, 39, 224-36	8.3	76
18	Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 1323-1326	2.9	29
17	The receptor binding affinity of monocyclic [Ala3,Xaa11]endothelin-1 analogs correlates with inducible helix length. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 113-24	3.4	5
16	Design and synthesis of nonpeptidal endothelin receptor antagonists based on the structure of a cyclic pentapeptide. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 253-258	2.9	6
15	Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors. *Journal of Medicinal Chemistry*, **1995**, 38, 659-68	8.3	33
14	Endothelin analogs which distinguish vasoconstrictor and vasodilator ETB receptors. *Life Sciences*, **1995**, 56, 1251-6	6.8	4

13	The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide. *Journal of Medicinal Chemistry*, **1994**, 37, 329-31	8.3	142
12	Control of peptide disulfide regioisomer formation by mixed cysteine-penicillamine bridges. Application to endothelin-1. *International Journal of Peptide and Protein Research*, **1993**, 42, 249-58		16
11	Structure-activity studies of endothelin leading to novel peptide ETA antagonists. *Bioorganic and Medicinal Chemistry*, **1993**, 1, 59-65	3.4	4
10	1-Benzazepin-2-one calcium channel blockers--VI. Receptor-binding model and possible relationship to desmethoxyverapamil. *Bioorganic and Medicinal Chemistry*, **1993**, 1, 285-307	3.4	17
9	Substrate based inhibitors of smooth muscle myosin light chain kinase. *Biochemical and Biophysical Research Communications*, **1992**, 185, 379-85	3.4	2
8	Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site. *Journal of Medicinal Chemistry*, **1992**, 35, 780-93	8.3	46
7	Peptide analogs of the pseudosubstrate domain of smooth muscle myosin light chain kinase inhibit actomyosin ATPase activity at concentrations that do not inhibit superprecipitation. *Biochemical and Biophysical Research Communications*, **1992**, 187, 1279-84	3.4	2
6	Venous smooth muscle contains vasoconstrictor ETB-like receptors. *Biochemical and Biophysical Research Communications*, **1992**, 184, 100-6	3.4	230
5	Solution conformation of a cyclic pentapeptide endothelin antagonist. Comparison of structures obtained from constrained dynamics and conformational search. *FEBS Letters*, **1992**, 299, 255-61	3.8	38
4	Structure-activity relationships of monocyclic endothelin analogs. *Bioorganic and Medicinal Chemistry Letters*, **1991**, 1, 33-38	2.9	31
3	Multiple pathways of thrombin-induced platelet activation differentiated by desensitization and a thrombin exosite inhibitor. *Biochemical and Biophysical Research Communications*, **1991**, 181, 636-43	3.4	39
2	Minimum requirements for inhibition of smooth-muscle myosin light-chain kinase by synthetic peptides. *Biochemical Journal*, **1989**, 257, 73-8	3.8	9
1	Hydroxyamino acid specificity of smooth muscle myosin light chain kinase. *Archives of Biochemistry and Biophysics*, **1988**, 260, 37-44	4.1	4